Evidence map›Paper›PMID 27865064›Full record

ArticleInfluenza and other respiratory viruses2017

Estimating vaccine effectiveness in preventing laboratory-confirmed influenza in outpatient settings in South Africa, 2015.

Johanna M McAnerney, Sibongile Walaza, Stefano Tempia, Lucille Blumberg, Florette K Treurnicht, Shabir A Madhi, Ziyaad Valley-Omar, Cheryl Cohen

Abstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Heterogeneity in influenza seasonality and vaccine effectiveness in Australia, Chile, New Zealand and South Africa: early estimates of the 2019 influenza season.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Johanna M McAnerneyNational Health Laboratory Services (NHLS), National Institute for Communicable Diseases (NICD), Johannesburg, South Africa.
Sibongile WalazaNational Health Laboratory Services (NHLS), National Institute for Communicable Diseases (NICD), Johannesburg, South Africa.
Stefano TempiaNational Health Laboratory Services (NHLS), National Institute for Communicable Diseases (NICD), Johannesburg, South Africa.
Lucille BlumbergNational Health Laboratory Services (NHLS), National Institute for Communicable Diseases (NICD), Johannesburg, South Africa.
Florette K TreurnichtNational Health Laboratory Services (NHLS), National Institute for Communicable Diseases (NICD), Johannesburg, South Africa.
Shabir A MadhiNational Health Laboratory Services (NHLS), National Institute for Communicable Diseases (NICD), Johannesburg, South Africa.
Ziyaad Valley-OmarNational Health Laboratory Services (NHLS), National Institute for Communicable Diseases (NICD), Johannesburg, South Africa.
Cheryl CohenNational Health Laboratory Services (NHLS), National Institute for Communicable Diseases (NICD), Johannesburg, South Africa.

Funding

Research on the Epidemiology,Prevention,Vaccine Effectiveness and Treatment of Influenza and Other Respiratory Viruses in South Africa.09U01IP001048 · IP · NATIONAL HEALTH LABORATORY SERVICE · PI COHEN, CHERYL · 2016 to 2020
$19.9M
NCIRD CDC HHS U01 IP001048
6 · The paper itself

Abstract

Trivalent seasonal influenza vaccine effectiveness during the 2015 season in South Africa was assessed using a test-negative case control study design. Influenza A(H1N1)pdm09 was the dominant circulating strain. Overall influenza vaccine coverage was 3.2% (29/899). The vaccine effectiveness estimate, against any influenza virus infection, adjusted for age, underlying conditions and timing within season was 46.2% (95% CI: -23.5 to 76.5), and 53.6% (95% CI: -62.6 to 80.3) against influenza A(H1N1)pdm09.

Indexed as

Vaccine PotencyAdultAgedCase-Control StudiesFemaleHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza B virusInfluenza, HumanInfluenza VaccinesMaleMiddle AgedOutpatientsSeasonsSentinel SurveillanceInfluenza Vaccineseffectivenessinfluenzavaccine

Identifiers

PMID27865064
PMCPMC5304569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.